PER-069-02已完成未知
ATAZANAVIR (BMS-232632) FOR THE TREATMENT OF PATIENTS INFECTED WITH HIV WHO COMPLETED THE CLINICAL TRIALS WITH ATAZANAVIR: A STUDY OF EXTENDED ACCESS.
BRISTOL MYERS SQUIBB PERU S.A.,0 个研究点目标入组 0 人开始时间: 2002年11月20日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Currently receiving atazanavir (unboosted or boosted with 100 mg ritonavir QD)and/or tenofovir-emtricitabine at time of screening and viral load is
- •≤ 10,000 copies/mL while on therapy
- •Subjects who are receiving investigational antiretroviral agents through Expanded Access Programs will be allowed to participate following discussion and approval by the BMS Medical Monitor
- •≥ 16 years of age (or minimum age as determined by local regulatory or as legal requirements dictate)
- •Both females of child-bearing potential and males must utilize effective barrier contraception to reduce transmission of sexually transmitted diseases, including HIV. Other contraception in addition to barrier methods are permitted, however interactions between atazanavir and oral contraceptives have not been studied
排除标准
- •WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the study
- •WOCBP using a prohibited contraceptive method (no contraceptive methods prohibited in this study. However, caution is warranted with coadministration of oral contraceptives)
- •Women who are pregnant or breastfeeding
- •Women with a positive pregnancy test on enrollment or prior to study drug administration, with the exception of women rolling over from AI424182, who may still have a positive β-HCG test at the time of enrollment
- •All subjects previously discontinued from an atazanavir study for any reason
- •Active alcohol or substance abuse sufficient, in the Investigator´s opinion, to prevent adequate compliance with study therapy or to increase the risk of developing pancreatitis or chemical hepatitis
- •Any other clinical conditions or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for study, or unable to comply with the dosing requirements
- •Any of the following laboratory values:
- •a) Serum creatinine ≥ 1.5 times the upper limit of normal,
- •b) Liver enzymes (AST, ALT) ≥ 5 times the upper limit of normal,
- •Hypersensitivity to any component of the formulation of study drug
- •Refer to Section 6.4.1 which details all prohibited therapies
- •Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study
研究者
相似试验
已完成
不适用
Atazanavir for HIV Infected Individuals: An Early Access Program-B24 Unspecified human immunodeficiency virus [HIV] diseaseUnspecified human immunodeficiency virus [HIV] diseaseB24PER-052-03BRISTOL MYERS SQUIBB COMPANY,
进行中（未招募）
1 期
Pilotstudy to asses the pharmacokinetics, the efficacy and safety of the combination of atazanavir, dolutegravir and lamivudine in HIV-1 infected patients who experience side-effects, toxicities or resistance to other anti-HIV drugs.HIVMedDRA version: 17.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2014-004488-19-NLRadboud University Medical Center20
已完成
不适用
THERAPEUTIC ALTERNATIVES FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS CPER-003-02SCHERING PLOUGH RESEARCH INSTITUTE,
已完成
不适用
Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access-B24 Unspecified human immunodeficiency virus [HIV] diseaseUnspecified human immunodeficiency virus [HIV] diseaseB24PER-008-08BRISTOL MYERS SQUIBB PERU S.A.,70
招募中
2 期
Amantadin as adjuvant therapy in the treatment of moderate to severe OCDObsessive-compulsive disorderObsessive- Cumpulsive Disorder.IRCT201705191556N99Tehran University of Medical Sciences50